TY - JOUR
T1 - Gastrointestinal stromal tumors
T2 - rationale for surgical adjuvant trials with imatinib.
AU - Cormier, Janice N.
AU - Patel, Shreyaskumar R.
AU - Pisters, Peter W.T.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2002/11
Y1 - 2002/11
N2 - Gastrointestinal stromal tumors (GISTs) constitute the majority of mesenchymal tumors involving the gastrointestinal tract. Over the past decade, it has been recognized that these tumors have distinctive immunohistochemical and genetic features. The expression of c-Kit (CD117), a transmembrane growth factor receptor, has emerged as an important defining feature of GISTs, and the pathogenesis of these tumors may be related to c-Kit mutations. Promising preclinical results have provided the driving force for the rapid clinical development of imatinib mesylate, a selective tyrosine kinase inhibitor of c-Kit. This novel molecularly targeted therapy has produced impressive clinical responses in a large proportion of patients with advanced GISTs and is under study as an adjuvant therapy in patients with localized resectable GISTs.
AB - Gastrointestinal stromal tumors (GISTs) constitute the majority of mesenchymal tumors involving the gastrointestinal tract. Over the past decade, it has been recognized that these tumors have distinctive immunohistochemical and genetic features. The expression of c-Kit (CD117), a transmembrane growth factor receptor, has emerged as an important defining feature of GISTs, and the pathogenesis of these tumors may be related to c-Kit mutations. Promising preclinical results have provided the driving force for the rapid clinical development of imatinib mesylate, a selective tyrosine kinase inhibitor of c-Kit. This novel molecularly targeted therapy has produced impressive clinical responses in a large proportion of patients with advanced GISTs and is under study as an adjuvant therapy in patients with localized resectable GISTs.
UR - http://www.scopus.com/inward/record.url?scp=0036835218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036835218&partnerID=8YFLogxK
U2 - 10.1007/s11912-002-0064-5
DO - 10.1007/s11912-002-0064-5
M3 - Review article
C2 - 12354363
AN - SCOPUS:0036835218
SN - 1523-3790
VL - 4
SP - 504
EP - 509
JO - Current oncology reports
JF - Current oncology reports
IS - 6
ER -